A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2− early breast cancer in the United States
A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2− early breast cancer in the United States
The National Comprehensive Cancer Network recommends that patients with hormone receptorpositive early breast cancer be considered for adjuvant endocrine therapy (ET) after primary treatment like surgical excision.